Condition
CIC-Rearranged Sarcoma
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT06414434Phase 1Active Not Recruiting
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
NCT06820957Phase 2Active Not RecruitingPrimary
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
NCT02389244Phase 2Active Not Recruiting
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Showing all 3 trials